Context
- India has transformed global healthcare through affordable generic medicines. Experts argue that the next frontier is making rare-disease drugs accessible and affordable.
- Unlike mass-market medicines, rare-disease drugs face a difficult economic model: small patient populations, expensive research and limited commercial demand.
- India can potentially address this through clinical research, regulatory facilitation, indigenous manufacturing and assured procurement.
Rare Diseases and Orphan Drugs
- A rare disease affects a relatively small number of people, but thousands of such diseases collectively create a substantial health burden.
- Around 7,000–8,000 rare diseases are known, while disease-specific treatments are available for only a small fraction.
- Orphan drugs are medicines developed to diagnose, prevent or treat rare diseases, where limited patient numbers traditionally weaken commercial incentives.
- India’s GenTIGS database compiles information on rare genetic disorders, associated genes and pathogenic variants, including disorders reported in India.
Why are Orphan Drugs Difficult to Develop?
- Small patient cohorts: Recruiting sufficient patients for conventional clinical trials is difficult.
- Trial-design challenge: Limited understanding of disease progression can make identifying reliable clinical endpoints difficult.
- High treatment cost: Research and specialised small-scale manufacturing costs are distributed across very few patients, increasing per-patient prices.
Global Model: Orphan Drug Incentives
- The US Orphan Drug Act, 1983 encouraged development through tax credits, research grants, user-fee exemptions and potential seven-year market exclusivity.
- Similar incentive frameworks subsequently emerged in the European Union and Japan.
- However, stimulating innovation does not automatically ensure affordability, making public financing and procurement important for patient access.
India’s Existing Framework
- The National Policy for Rare Diseases (NPRD), 2021 provides the principal framework for prevention, diagnosis and treatment of rare diseases.
- It facilitates financial and medical support of up to ₹50 lakh per eligible patient for 63 identified rare diseases.
- The network has expanded from 8 Centres of Excellence (CoEs) in 2021 to 16 by July 2026, improving specialised diagnosis and treatment capacity.
Why India Can Become an Orphan-Drug Hub
- Patient base: India’s large population can provide meaningful absolute patient numbers even for individually rare conditions, supporting research and trials.
- Genetic diversity: Diverse population groups and patterns of endogamy and consanguinity make India important for studying rare genetic variants.
- Pharmaceutical capability: India’s strong generic, biosimilar and emerging advanced-therapy ecosystem provides a foundation for lower-cost domestic manufacturing.
Regulatory Opportunity
- Under the New Drugs and Clinical Trials Rules, 2019, eligible orphan drugs already approved and marketed in specified jurisdictions may be considered for waiver of local clinical trials, subject to prescribed conditions and safeguards.
- The specified jurisdictions include the USA, UK, Japan, Australia, Canada and European Union.
- This can reduce unnecessary duplication and accelerate access without dispensing with regulatory scrutiny.
Building an Affordable Orphan-Drug Ecosystem
Experts propose moving beyond treatment financing towards domestic capacity creation through:
- Targeted incentives: Tax or production support to de-risk small-volume manufacturing.
- Technology partnerships: Collaboration among global innovators, Indian companies and public research institutions.
- Advance Market Commitments: Assured government procurement to create predictable demand.
- Benefit-sharing: Indian patients participating in research should receive fair and affordable access to resulting therapies.
The goal should be to transform India from primarily financing expensive rare-disease therapies to developing and manufacturing affordable treatments.
FAQs
Q1. What is an orphan drug?
A medicine developed for the diagnosis, prevention or treatment of a rare disease.
Q2. Which policy addresses rare diseases in India?
The National Policy for Rare Diseases, 2021.
Q3. What financial assistance is available under NPRD?
Eligible patients can receive support of up to ₹50 lakh per patient.
Q4. What is an Advance Market Commitment?
It is an advance commitment to purchase a product, providing manufacturers with predictable demand.
Q5. Why is India suited for orphan-drug development?
India combines a large and genetically diverse population, research potential and strong pharmaceutical manufacturing capacity.
